What is the difference between Section 361 and Section 351 HCT/Ps?

Section 361 HCT/Ps are minimally manipulated tissues intended for homologous use that do not rely on living cell metabolic activity, exempting them from premarket FDA approval. Section 351 products involve more than minimal manipulation or non-homologous use, requiring an Investigational New Drug (IND) application or Biologics License Application (BLA).

What state licenses must a biologics distributor hold in Texas?

In Texas, distributors of human tissue and medical products must hold appropriate state licensing from the Texas Department of State Health Services (DSHS). They must also adhere to federal FDA 21 CFR Part 1271 regulations for tissue distribution and handling.

What documentation should a practice require for every biologics shipment?

Practices should require a product-specific Certificate of Analysis (CoA) matching the shipment lot number, temperature-monitoring verification, donor screening documentation, and clear instructions for storage and handling.

How should cryopreserved tissue allografts be stored in a clinical setting?

Cryopreserved tissues typically require ultra-low temperature freezers operating at -80°C or liquid nitrogen vapor storage, along with continuous temperature logging and emergency alarm systems to prevent temperature excursions.

Why is lot-to-lot traceability essential for medical practices?

Lot-to-lot traceability links specific donor tissue shipments to individual patient records. This enables immediate identification and contact tracing in the event of a product inquiry, regulatory audit, or vendor safety recall.

How to Select a Compliant Regenerative Biologics Vendor

Selecting a compliant regenerative medicine biologics vendor requires validating tissue bank accreditation, verifying FDA HCT/P Section 361 compliance status, and demanding batch-specific Certificates of Analysis. Conducting this structured audit protects your medical license and practice operations from regulatory enforcement linked to unapproved biologic drugs. Explore our essential vetting checklist to evaluate tissue sourcing transparency, cold-chain logs, and distributor credentials before ordering.

Regulatory Framework: Navigating HCT/P Classifications

When introducing biologics such as autologous PRP, tissue scaffolds, or human cellular and tissue-based products into clinical practice, compliance starts with understanding federal regulatory definitions. The U.S. Food and Drug Administration (FDA) regulates Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under Title 21 of the Code of Federal Regulations (CFR), specifically Part 1271.

Section 361 vs. Section 351 Status

To maintain regulatory compliance, practices must distinguish between products regulated solely under Section 361 of the Public Health Service (PHS) Act and those regulated as biological drugs under Section 351.

Section 361 HCT/Ps: These products are minimally manipulated, intended strictly for homologous use, and do not rely on the metabolic activity of living cells for primary function. They do not require premarket approval, provided they fulfill all criteria under 21 CFR 1271.10.
Section 351 Products: Tissues or cellular products that undergo more than minimal manipulation, are promoted for non-homologous applications, or rely on living cell metabolism fall under Section 351. These require an Investigational New Drug (IND) application or a Biologics License Application (BLA).

Purchasing products from a vendor claiming Section 361 status while promoting non-homologous indications exposes your practice to legal and compliance risks, including warning letters and enforcement actions. Practice administrators must verify that every tissue product in their inventory aligns with current regulatory guidance.

Essential Evaluation Checklist for Practice Managers

Evaluating potential suppliers requires a rigorous vetting process that extends beyond pricing and catalog availability. Practice administrators should use the following checklist when conducting vendor due diligence:

State Licensing and Registration: Verify that the distributor holds active medical device and tissue/drug distributor licenses in your state. For instance, Texas tissue suppliers must maintain active licensure with the Texas Department of State Health Services (DSHS).
FDA Establishment Registration: Confirm that both the processing tissue bank and the vendor maintain active registration on the FDA Establishment Registration system for HCT/Ps.
Tissue Bank Accreditation: Ensure human tissue allografts originate from tissue banks accredited by recognized bodies such as the American Association of Tissue Banks (AATB), which mandates strict quality management systems.
Donor Screening Protocols: Request written verification detailing donor eligibility testing for relevant communicable diseases (including HIV, Hepatitis B, Hepatitis C, HTLV, and Syphilis) performed by CLIA-certified laboratories.
Certificates of Analysis (CoA): Require product-specific, lot-numbered Certificates of Analysis for every shipment, confirming sterility testing, endotoxin screening, and structural characterization.
Cold-Chain Logistics Verification: Confirm that the vendor utilizes continuous temperature monitoring during transport (e.g., dry ice, liquid nitrogen phase, or validated thermal packaging) and provides precise storage handling instructions upon delivery.
Traceability and Recall Infrastructure: Audit the vendor's track record and internal software for rapid inventory tracking, batch trace-backs, and immediate product notification protocols.

Clinical Considerations: Evaluating Safety and Structural Integrity

While practice managers handle procurement logistics and legal risk, treating physicians must evaluate product characteristics, handling performance, and safety protocols. For regenerative medicine doctors, working with a transparent vendor ensures clinical predictability across surgical and outpatient suites.

Processing Methods and Tissue Preservation

The method used to harvest, process, and preserve tissue allografts directly impacts matrix structure and clinical handling. Cryopreservation requires controlled-rate freezing protocols and ultra-low temperature storage (-80°C or colder) to protect tissue integrity. Lyophilization (freeze-drying) offers shelf-stable ambient storage but requires precise reconstitution protocols prior to placement. Clinicians must understand how processing techniques—such as terminal sterilization via gamma irradiation or aseptic processing—affect tissue characteristics for specific restorative procedures.

Lot-to-Lot Consistency and Characterization

Biologic products derived from donor tissue naturally exhibit biological variability. High-quality vendors minimize variance by enforcing strict donor selection criteria and standardized processing SOPs. Clinicians should request characterization data and processing documentation to ensure consistent tissue administration and predictable intraoperative handling.

Operational Risk Mitigation and Inventory Management

Integrating advanced biologics into daily practice operations introduces workflow overhead related to inventory control, storage monitoring, and chain-of-custody logging.

Storage Infrastructure: Ultra-low temperature freezers (-80°C) or liquid nitrogen phase dewars require dedicated circuit protection, continuous temperature logging, and visual or audible alarm systems to prevent inventory loss during power interruptions.
Receiving Protocols: Staff must inspect shipment temperature indicators upon arrival, log lot numbers into the practice management system immediately, and place products into appropriate storage units.
Patient Record Logging: Every procedure involving an tissue allograft requires double-sticker lot tracking—attaching one label to the clinical chart and retaining another in the facility tissue log for regulatory auditing.

What This Means for Your Practice

Selecting a compliant vendor transforms biologics from a potential compliance liability into a secure, streamlined practice offering. To execute this transition in your facility:

Audit Current Inventory: Review existing tissue and biologic suppliers against FDA establishment registrations, state licensing, and CoA completeness.
Establish Standardized SOPs: Implement standard operating procedures for receiving shipments, recording storage temperatures, and logging lot numbers into electronic health records.
Request Regulatory Dossiers: Require prospective vendors to supply full compliance documentation before issuing purchase orders.
Educate Clinical and Operations Teams: Train practice administrators and clinical teams on regulatory boundaries regarding minimal manipulation and homologous use.

Partnering with a Compliant Distributor

Navigating the regulatory landscape of biologic procurement, cold-chain maintenance, and tissue storage requires an experienced medical distribution partner. Dallas Regenerative Solutions holds active Texas state licensing (license #1002308) and maintains rigorous supplier auditing to support practice safety and operational stability.

To learn more about compliant biologics sourcing or to review our verification standards, explore our frequently asked questions or contact our clinical consulting team today.